US Biosimilar Pathway Unlikely to be Used.
- Published in:
- BioDrugs, 2011, v. 25, n. 1, p. 63, doi. 10.2165/11588410-000000000-00000
- Publication type:
- Article
Works matching IS 11738804 AND DT 2011 AND VI 25 AND IP 1
Results: 8
1
2
Spotlight on Rituximab in Chronic Lymphocytic Leukemia, Low-Grade or Follicular Lymphoma, and Diffuse Large B-Cell Lymphoma.
- Published in:
- BioDrugs, 2011, v. 25, n. 1, p. 55, doi. 10.2165/11206980-000000000-00000
- Publication type:
- Article
3
Lapatinib in Postmenopausal Women with Hormone Receptor-Positive, HER2-Positive Metastatic Breast Cancer.
- Published in:
- BioDrugs, 2011, v. 25, n. 1, p. 53, doi. 10.2165/11207270-000000000-00000
- Publication type:
- Article
4
Ecallantide in Acute Hereditary Angioedema.
- Published in:
- BioDrugs, 2011, v. 25, n. 1, p. 51, doi. 10.2165/11206960-000000000-00000
- Publication type:
- Article
5
Optimizing the Efficacy of First-Line Chemotherapy plus Bevacizumab in Metastatic Colorectal Cancer.
- Published in:
- BioDrugs, 2011, v. 25, n. 1, p. 43, doi. 10.2165/11584680-000000000-00000
- Publication type:
- Article
6
MicroRNA Epigenetics.
- Published in:
- BioDrugs, 2011, v. 25, n. 1, p. 27
- Publication type:
- Article
7
New Anti-CD20 Monoclonal Antibodies for the Treatment of B-Cell Lymphoid Malignancies.
- Published in:
- BioDrugs, 2011, v. 25, n. 1, p. 13, doi. 10.2165/11539590-000000000-00000
- Publication type:
- Article
8
Optimizing Therapeutic Antibody Function.
- Published in:
- BioDrugs, 2011, v. 25, n. 1, p. 1, doi. 10.2165/11537830-000000000-00000
- Publication type:
- Article